RAHWAY, N.J. — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study evaluating zilovertamab vedotin in combination with standard of care rituximab and gemcitabine-oxaliplatin (R-GemOx) for the treatment of relapsed or refractory...
treatment News
Rahway, New Jersey – Merck’s blockbuster PD-1 inhibitor Keytruda (pembrolizumab) improved overall survival when used as an adjuvant treatment for renal cell carcinoma patients who are at intermediate-high or high risk of recurrence after nephrectomy, according to results of the Phase III KEYNOTE-564 trial posted Saturday. Compared with placebo, patients...
Study also met secondary endpoint of overall survival (OS) for patients whose tumors express PD-L1 KEYTRUDA® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first immune checkpoint inhibitor-based regimen to show a statistically significant improvement in OS for ovarian cancer RAHWAY, N.J. — Merck (NYSE: MRK), known as...
RAHWAY, N.J. — Merck & Co. (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced resectable...
NEW YORK, NY — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD) who fail corticosteroids, and the high mortality in these patients, Mesoblast and...
Melbourne, Australia and New York, USA – Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatorydiseases, today provided a regulatory update on remestemcel-L for steroid-refractory acute graft versus host disease in children following its recent meeting with the FDA’s OTAT. Mesoblast requested the meeting to address the...
NEW YORK, NY — Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from the FDA for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age...
Hefei, China – A research group led by Prof. WANG Hui from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences has introduced a metal-free nanozyme based on graphene quantum dots (GQDs) for highly efficient tumor chemodynamic therapy (CDT). The study was published in Matter. GQDs...
Zurich, Switzerland – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA’s...
Chongqing, China – Metronomic chemotherapy (MC) is emerging as a groundbreaking treatment for pediatric neuroblastoma, offering a more accessible and manageable option for children with high-risk and relapsed/refractory forms of the disease. This innovative approach could revolutionize care, particularly in low-resource settings where traditional treatments are often out of reach....